EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Towards FLASH Radiotherapy in Lung Cancer: A Review on Preclinical Evidence and Technical Feasibility

Simone N Visser iD, Steven J M Habraken iD, Anggraeini Puspitasari-Kokko iD, Anne H Zur Horst iD, Coen R N Rasch iD, Krista C J van Doorn-Wink iD

Cancers · 27.07.2026 · 18 (15) · 2418

DOI: 10.3390/cancers18152418 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.07.2026. Verfasst von Simone N Visser und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Leiden University Medical Center (LUMC), 2333 ZA Leiden, The Netherlands. Die Arbeit nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Varian Medical Systems (United States).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Alongside surgery and systemic treatments, radiotherapy plays a crucial role in the treatment of lung cancer but can affect healthy tissue and cause serious side effects. Compared to photon therapy, proton therapy can lower toxicity because protons deposit most of their energy within the tumor (the Bragg peak), sparing healthy tissue. FLASH radiotherapy (FLASH-RT), which is characterized by using ultra-high dose rates (UHDR), may further enhance healthy tissue sparing. Preclinical studies using electrons, protons, or photons have shown that FLASH-RT may reduce toxicity, while tumor response is maintained, known as the FLASH-effect. FLASH-RT with protons (FLASH-PT) is a promising treatment for lung cancer, integrating the biological advantages of FLASH with the physical advantages of proton beams.

Methods

A literature search was performed on preclinical evidence of the FLASH-effect on lung-related endpoints, the proposed mechanisms, and treatment planning and delivery strategies for FLASH-PT in lung cancer.

Results

Preclinical studies have shown reduced pulmonary fibrosis, inflammation, vascular damage, and oxidative stress with FLASH-RT. Current evidence suggests that the FLASH-effect likely arises from multiple radiochemical and biological processes, can vary between tissues, and depends on dose, beam and/or delivery characteristics. Despite growing evidence, the exact dose delivery conditions and technological factors required to obtain a FLASH-effect remain unclear. Treatment planning studies achieved clinically acceptable thoracic FLASH-PT plans for lung cancer, with similar or improved organ-at-risk sparing compared with conventional radiotherapy, while meeting (fraction) dose and dose rate criteria for the FLASH-effect. However, clinically feasible technologies for conformal dose delivery under UHDR conditions with respiratory motion mitigation are still under development.

Conclusions

FLASH-PT holds the potential to reduce radiation-induced pulmonary side effects and expand the therapeutic window of radiotherapy. Still, key (pre)clinical and technological challenges must be addressed before clinical implementation for patients with lung cancer.

Schlagwörter

Stichwörter der Autor:innen

FLASH radiotherapyFLASH-effectlung cancermotion managementproton therapyultra-high dose rate

Autor:innen und Institutionen

  • Department of Radiation Oncology, Leiden University Medical Center (LUMC), 2333 ZA Leiden, The Netherlands.
  • Holland Proton Therapy Center (HollandPTC), 2629 JH Delft, The Netherlands.
  • Department of Radiation Oncology, Erasmus Medical Center (EMC), 3015 GD Rotterdam, The Netherlands.

ORCID-Profile: Simone N Visser, Steven J M Habraken, Anggraeini Puspitasari-Kokko, Anne H Zur Horst, Coen R N Rasch, Krista C J van Doorn-Wink

Förderung

  • Varian Medical Systems (United States)

Zitieren

APA

Visser, S. N., Habraken, S. J. M., Puspitasari-Kokko, A., Zur Horst, A. H., Rasch, C. R. N., & van Doorn-Wink, K. C. J. (2026). Towards FLASH Radiotherapy in Lung Cancer: A Review on Preclinical Evidence and Technical Feasibility. Cancers, 18(15), 2418. https://doi.org/10.3390/cancers18152418

Vancouver

Visser SN, Habraken SJM, Puspitasari-Kokko A, Zur Horst AH, Rasch CRN, van Doorn-Wink KCJ. Towards FLASH Radiotherapy in Lung Cancer: A Review on Preclinical Evidence and Technical Feasibility. Cancers. 2026;18(15):2418. doi:10.3390/cancers18152418

BibTeX
@article{Visser2026,
  author = {Visser, Simone N and Habraken, Steven J M and Puspitasari-Kokko, Anggraeini and Zur Horst, Anne H and Rasch, Coen R N and van Doorn-Wink, Krista C J},
  title = {Towards FLASH Radiotherapy in Lung Cancer: A Review on Preclinical Evidence and Technical Feasibility},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {15},
  pages = {2418},
  doi = {10.3390/cancers18152418}
}
Kostenlos starten →